



# Celebrating Two Decades of Targeted Protein Degradation



2001

Arvinas founder, Craig Crews, and team publish the first major publication describing heterobifunctional protein degraders

2004

The first cell-permeable heterobifunctional protein degrader is reported

Aaron Ciechanover, Avram Hershko and Irwin Rose are jointly awarded the Nobel Prize for the discovery of ubiquitin-mediated protein degradation

2004

2008

The first small-molecule heterobifunctional protein degrader is identified

Novel peptidomimetic ligands for the VHL E3 are developed in Craig Crews' laboratory

2012

2013

**Arvinas** is founded  
First evidence is published that heterobifunctional protein degraders function in vivo

2018

**Arvinas** first creates PROTAC protein degraders that cross the blood-brain barrier

**Arvinas** first creates orally bioavailable PROTAC<sup>®</sup> protein degraders

2016

2019

**Arvinas** announces a partnership with Bayer, including a pharmaceutical collaboration and the launch of an agricultural joint venture, Oerth Bio, to explore the use of PROTAC protein degraders in plant biology

**Arvinas** begins first ever clinical study of a targeted protein degrader: ARV-110, for the potential treatment of men with metastatic castration-resistant prostate cancer, soon followed by ARV-471 for patients with ER+ breast cancer

2019

2020

**Arvinas** releases clinical data demonstrating efficacy proof-of-concept for PROTAC protein degraders ARV-471 and ARV-110

2021

**Arvinas** celebrates two decades of progress in protein degradation

THE  
FUTURE



Oncology, Immunology,  
Neuroscience, Agriculture,  
Cardiovascular Disease

By the end of 2021, at least 15 deliberately designed degraders are anticipated to be in the clinic.

ARVINAS